EXAMPLE:

1. Isolation of primary cells from PBMC
CD4+ T cells, CD8+ T cells, and monocytes were isolated from PBMC, and the purity is ≥95%.

Fig 1. Isolation of primary cells for the in vitro efficacy assay

2. MLR Assay
PD-L1+ DCs were co-cultured with allogeneic CD4+ T cells. Activity of T cells were suppressed by the PD-1/PD-L1 checkpoint which can be rescued by the addition of anti-PD-L1 antibodies (Fig 2). It demonstrated that the candidate antibody possesses checkpoint inhibitory activity comparable to the other three approved mAb drugs (Benchmark 1-3).

Fig 2. Expression of IL-2 (left) and IFN-γ (right) in the MLR Assay

SERVICE:

Service	Input	Time	Output	Price
MLR Assay	Samples (e.g. antibody) and Reference samples	2~3 weeks	Report	$ 4,999 per 96-well plate

Do you need assistance with MLR evaluation?

ADCC | ADCP | CDC | Internalization | Cross-reactivity | Tumor growth inhibition | Learn more


ABOUT US:

Sanyou Biopharmaceuticals is a leading international High-tech biotechnology company focused on research, development and providing integrated solutions for innovative antibody drug developments.

Sanyou is committed to building world-leading antibody drug discovery and development platforms of high-quality, high-throughput, integrated R&D and value transformation. Sanyou is dedicated in constructing a business ecosystem for therapeutic, R&D and diagnostic products and services, and collaborating with global biopharmaceutical, diagnostic, R&D companies to open a new era for the diagnosis and treatment of human diseases.

Since the founding in the year of 2015, Sanyou has been growing rapidly. As of November 2020, Sanyou has a professional team of more than 150 employees, of which more than 70% hold a PhD or master degree, and this team is deeply experienced in R&D and industrialization of innovative drugs. Sanyou has established an integrated R&D laboratory of several thousands of square meters with advanced facilities in Caohejing Hi-Tech Park in Shanghai. The laboratory has 10 functional modules and more than 40 core technology platforms, led by a series of super-trillion phage display antibody libraries, and followed by a full range of essential R&D platforms for innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, pharmaceutical properties analysis, cell line construction, and process development. Sanyou continues to provide new technologies, new products, services and solutions of "best quality, fastest speed and lowest cost". Sanyou has established friendly business relationships with more than 100 pharmaceutical companies, drug development organizations and diagnostic product development companies around the world.

"Excellence and innovation, pursuit of dreams, striving and evolving, for the benefit of patients", holding these principles and beliefs, Sanyou looks forward to working with our customers and partners to build a long-term synergistic growth ecosystem and a healthy society.

You're welcome to send an email and tell us what's your need, and we will get back to you ASAP.

Sincerely.

Qingyang